MedTrace Logo

Clinical Study of IAH0968 in Patients With HER2-positive Advanced Solid Tumors

NCT04934514 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 97

Last updated 2024-02-20

No results posted yet for this study

Summary

This is a phase I/IIa study to evaluate the safety, tolerability and preliminary efficacy of IAH0968 in patients with HER2-positive advanced solid tumors who have failed standard treatment.

Conditions

  • Advanced Solid Tumor

Interventions

BIOLOGICAL

IAH0968

IAH0968 is an investigational product.

DRUG

Gemcitabine

Gemcitabine 1000 mg/m\^2 intravenous infusion

DRUG

Cisplatin

Cisplatin 75 mg/m\^2 intravenous infusion

Sponsors & Collaborators

  • SUNHO（China）BioPharmaceutical CO., Ltd.

    lead INDUSTRY

Principal Investigators

  • Yunpeng Liu, MD · First Hospital of China Medical University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-06
Primary Completion
2024-12-31
Completion
2025-03-31
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04934514 on ClinicalTrials.gov